CN1094406A - 用于治疗人体识别障碍的3，3′-二取代的-1，3-二氢-2H-吡咯[2，3-b]杂环-2-酮 - Google Patents

用于治疗人体识别障碍的3，3′-二取代的-1，3-二氢-2H-吡咯[2，3-b]杂环-2-酮 Download PDF

Info

Publication number
CN1094406A
CN1094406A CN93119623A CN93119623A CN1094406A CN 1094406 A CN1094406 A CN 1094406A CN 93119623 A CN93119623 A CN 93119623A CN 93119623 A CN93119623 A CN 93119623A CN 1094406 A CN1094406 A CN 1094406A
Authority
CN
China
Prior art keywords
phenyl
alkyl
compound
pyridylmethyl
dihydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN93119623A
Other languages
English (en)
Chinese (zh)
Inventor
W·W·韦尔克森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Pharma Co
Original Assignee
DuPont Merck Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DuPont Merck Pharmaceutical Co filed Critical DuPont Merck Pharmaceutical Co
Publication of CN1094406A publication Critical patent/CN1094406A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN93119623A 1992-09-18 1993-09-18 用于治疗人体识别障碍的3，3′-二取代的-1，3-二氢-2H-吡咯[2，3-b]杂环-2-酮 Pending CN1094406A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US947,152 1992-09-18
US07/947,152 US5278162A (en) 1992-09-18 1992-09-18 3,3'-disubstituted-1,3-dihydro-2H-pyrrolo[2,3-b]heterocyclic-2-one useful in the treatment of cognitive disorders of man

Publications (1)

Publication Number Publication Date
CN1094406A true CN1094406A (zh) 1994-11-02

Family

ID=25485622

Family Applications (1)

Application Number Title Priority Date Filing Date
CN93119623A Pending CN1094406A (zh) 1992-09-18 1993-09-18 用于治疗人体识别障碍的3，3′-二取代的-1，3-二氢-2H-吡咯[2，3-b]杂环-2-酮

Country Status (10)

Country Link
US (1) US5278162A (https=)
EP (1) EP0660833A1 (https=)
JP (1) JPH08501550A (https=)
CN (1) CN1094406A (https=)
AU (1) AU4856893A (https=)
CA (1) CA2144636A1 (https=)
IL (1) IL107003A0 (https=)
TW (1) TW248560B (https=)
WO (1) WO1994006793A1 (https=)
ZA (1) ZA936872B (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5296478A (en) * 1992-10-07 1994-03-22 The Dupont Merck Pharmaceutical Co. 1-substituted oxindoles as cognition enhancers
CA2188427C (en) 1994-04-29 2000-06-27 Robert A. Volkmann Neurotransmitter release enhancers
US5744476A (en) * 1994-06-27 1998-04-28 Interneuron Pharmaceuticals, Inc. Dopamine D1 agonists for the treatment of dementia
AR056968A1 (es) * 2005-04-11 2007-11-07 Xenon Pharmaceuticals Inc Compuestos espiro-oxindol y composiciones farmacéuticas
AR053710A1 (es) * 2005-04-11 2007-05-16 Xenon Pharmaceuticals Inc Compuestos espiroheterociclicos y sus usos como agentes terapeuticos
AR053713A1 (es) * 2005-04-20 2007-05-16 Xenon Pharmaceuticals Inc Compuestos heterociclicos y sus usos como agentes terapeuticos
US20110294842A9 (en) * 2006-10-12 2011-12-01 Xenon Pharmaceuticals Inc. Spiro (furo [3, 2-c] pyridine-3-3' -indol) -2' (1'h)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain
AU2007307635A1 (en) * 2006-10-12 2008-04-17 Xenon Pharmaceuticals Inc. Tricyclic spiro-oxindole derivatives and their uses as therapeutic agents
WO2008060789A2 (en) * 2006-10-12 2008-05-22 Xenon Pharmaceuticals Inc. Use of spiro-oxindole compounds as therapeutic agents
CA2741024A1 (en) * 2008-10-17 2010-04-22 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their use as therapeutic agents
JO3032B1 (ar) * 2008-10-17 2016-09-05 Xenon Pharmaceuticals Inc مركبات سبيرو – اوكسندول وإستعمالاتها كعوامل علاجية.
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
KR20120099429A (ko) 2009-10-14 2012-09-10 제논 파마슈티칼스 인크. 스피로-옥스인돌 화합물의 합성 방법
US20110086899A1 (en) * 2009-10-14 2011-04-14 Xenon Pharmaceuticals Inc. Pharmaceutical compositions for oral administration
WO2011106729A2 (en) 2010-02-26 2011-09-01 Xenon Pharmaceuticals Inc. Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents
WO2016127068A1 (en) 2015-02-05 2016-08-11 Teva Pharmaceuticals International Gmbh Methods of treating postherpetic neuralgia with a topical formulation of a spiro-oxindole compound

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4760083A (en) * 1986-04-10 1988-07-26 E. I. Dupont De Nemours & Company 3,3-disubstituted indolines
GB8714371D0 (en) * 1987-06-19 1987-07-22 Smith Kline French Lab Process
WO1989012637A1 (en) * 1988-06-14 1989-12-28 Schering Corporation Heterobicyclic compounds having antiinflammatory activity
US5006537A (en) * 1989-08-02 1991-04-09 Hoechst-Roussel Pharmaceuticals, Inc. 1,3-dihydro-1-(pyridinylamino)-2H-indol-2-ones

Also Published As

Publication number Publication date
CA2144636A1 (en) 1994-03-31
ZA936872B (en) 1995-03-17
AU4856893A (en) 1994-04-12
TW248560B (https=) 1995-06-01
WO1994006793A1 (en) 1994-03-31
JPH08501550A (ja) 1996-02-20
IL107003A0 (en) 1993-12-28
EP0660833A1 (en) 1995-07-05
US5278162A (en) 1994-01-11

Similar Documents

Publication Publication Date Title
JP5816353B2 (ja) 新規ピラゾール誘導体
JP2023052415A (ja) ピリミジニルチロシンキナーゼ阻害剤
JP5982397B2 (ja) Ｆａａｈ阻害剤
CN103038229B (zh) 杂芳基化合物及其使用方法
JP6039800B2 (ja) Ｅｇｆｒ活性を調節するための化合物および組成物
CN1094406A (zh) 用于治疗人体识别障碍的3，3′-二取代的-1，3-二氢-2H-吡咯[2，3-b]杂环-2-酮
JP2024501641A (ja) 置換大環状化合物及び関連する治療方法
CN1347414A (zh) 对多巴胺d3受体具有亲和力的三唑化合物
IL262722A (en) Compounds from combined pressure response modulators, preparations containing them and their uses
KR20200089718A (ko) 인돌 화합물 및 이의 용도
KR20110096129A (ko) 오렉신 길항제로서 유용한 피페리딘 유도체
JP2017506675A (ja) Ｔｙｋ２阻害剤およびその使用
TW202028205A (zh) 酪胺酸蛋白質激酶2(tyk2)抑制劑及其用途
JP2010531848A (ja) オレキシン受容体アンタゴニストとして有用なピペリジン誘導体
CN1777602A (zh) 作为5－羟基色胺－6配体的杂环基－3－磺酰基氮杂吲哚或－氮杂吲唑衍生物
JP2010531849A (ja) オレキシン受容体アンタゴニストとしてのイミダゾ［１，２−ｃ］ピリミジン−２−イルメチルピペリジン誘導体
KR20180110132A (ko) 무스카린성 아세틸콜린 수용체 m1의 양성 알로스테릭 조절제
JP2023554282A (ja) 置換ピペリジノ化合物及び関連する治療方法
KR20200081424A (ko) 무스카린성 아세틸콜린 수용체 m4의 길항제
TW201840559A (zh) Tyk2抑制劑、其用途及生產方法
BR112019018688A2 (pt) derivados de imidazo[4,5-c] quinolina como inibidores de lrrk2
JP7391012B2 (ja) オレキシン受容体拮抗薬としての置換２－アザビシクロ［３．１．１］ヘプタンおよび２－アザビシクロ［３．２．１］オクタン誘導体
CN109689656B (zh) 7-取代的1-芳基二氮杂萘-3-羧酰胺及其用途
CN1206414A (zh) 作为速激肽拮抗剂的n－酰基－2－取代的－4－(苯并咪唑基或咪唑并吡啶基取代的残基)哌啶
CN107344942B (zh) 调节电压门控钠通道的化合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication